<DOC>
	<DOCNO>NCT00026195</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Aging may affect way drug work . PURPOSE : Phase I trial determine relationship age effectiveness irinotecan treat patient solid tumor .</brief_summary>
	<brief_title>Irinotecan Treating Aging Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether relationship pharmacokinetic characteristic irinotecan age patient non-hematologic malignancy . - Determine whether relationship toxic effect drug age patient . - Determine whether relationship genotype ( UGT1A1 , CYP3A , relevant gene ) phenotype ( pharmacokinetics , toxicity ) affect age patient treat drug . - Analyze data collect co-morbid condition concurrent medication patient treated drug . OUTLINE : This multicenter study . Patients stratify accord age ( 18 55 v 70 ) . Patients receive irinotecan IV 90 minute weekly 4 week . Treatment continue absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 140 patient ( 70 per stratum ) accrue study within 3.5 year .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nonhematologic malignancy Brain metastasis primary brain tumor eligible provide patient receive steroid antiepileptic medication PATIENT CHARACTERISTICS : Age : 18 55 70 Performance status : CTC 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT great ULN Renal : Creatinine great ULN Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosourea ) No 1 prior chemotherapy regimen metastatic disease ( limit administer adjuvant setting ) No prior camptothecin Endocrine therapy : See Disease Characteristics Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy , include palliation Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>